Similar articles

Abstract: The present study was conducted to clarify the therapeutic effect of cornuside on experimental autoimmune encephalomyelitis (EAE) and its influence on T helper 17 (Th17) cell and regulatory T (Treg) cell infiltration into the central nervous system. Rats were randomly placed into four treatment groups: control, EAE, EAE+cornuside, and EAE+prednisolone. The neurological function scores of rats were assessed daily. On the second day after EAE rats began to show neurological deficit symptoms, the four groups were treated with normal saline, normal saline, cornuside (150 mg/kg), and prednisolone (5 mg/kg), respectively. The treatment was discontinued after two weeks, and the spinal cord was obtained for hematoxylin and eosin (H&E) and luxol fast blue staining, as well as retinoic acid receptor-related orphan receptor γ (RORγ) and forkhead box protein P3 (Foxp3) immunohistochemical staining. Blood was collected for Th17 and Treg cell flow cytometry testing, and the serum levels of interleukin (IL)-17A, IL-10, transforming growth factor-β (TGF-β), IL-6, IL-23, and IL-2 were measured via enzyme-linked immunosorbent assay (ELISA). Compared with rats in the EAE group, rats in the EAE+cornuside and EAE+prednisolone groups began to recover from neurological deficits earlier, and had a greater degree of improvement of symptoms. Focal inflammation, demyelination, and RORγ-positive cell infiltration were reduced by cornuside or prednisolone treatment, whereas the Foxp3-positive cell numbers were not significantly different. Meanwhile, the number of Th17 cells and the IL-17A, IL-6, and IL-23 levels were lower in the blood after cornuside or prednisolone treatment, whereas the number of Treg cells or the levels of IL-10, TGF-β, and IL-2 were not markedly different. cornuside can alleviate symptoms of EAE neurological deficits through its anti-inflammatory and immunosuppressive effects, and Th17 cells may be one of its therapeutic targets.

山茱萸新苷通过抑制Th17细胞浸润中枢神经系统缓解实验性自身免疫性脑脊髓炎

[1]BalasaR, BarcuteanL, BalasaA, et al., 2020. The action of Th17 cells on blood brain barrier in multiple sclerosis and experimental autoimmune encephalomyelitis. Hum Immunol, 81(5):237-243.

[2]BurrowsDJ, McGownA, JainSA, et al., 2019. Animal models of multiple sclerosis: from rodents to zebrafish. Mult Scler J, 25(3):306-324.

[3]CerboniS, GehrmannU, PreiteS, et al., 2020. Cytokine-regulated Th17 plasticity in human health and diseases. Immunology, 163(1):13280.

[4]DingHY, XieYN, DongQ, et al., 2019. Roles of hyaluronan in cardiovascular and nervous system disorders. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 20(5):428-436.

[5]DobsonR, GiovannoniG, 2019. Multiple sclerosis—a review. Eur J Neurol, 26(1):27-40.

[6]DongY, FengZL, ChenHB, et al., 2018. Corni Fructus: a review of chemical constituents and pharmacological activities. Chin Med, 13:34.

[7]DurantL, WatfordWT, RamosHL, et al., 2010. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity, 32(5):605-615.

[8]FanYP, WuW, 2014. Syndrome factors of multiple sclerosis in 500 patients. J Beijing Univ Tradit Chin Med, 37(1):68-72 (in Chinese).

[9]FanYP, WangSQ, 2018. Standard for clinical diagnosis and treatment of traditional chinese medicine for multiple sclerosis/neuromyelitis optica. J Cap Med Univ, 39(6):833-835 (in Chinese).

[10]FaschingP, StradnerM, GraningerW, et al., 2017. Therapeutic potential of targeting the Th17/Treg axis in autoimmune disorders. Molecules, 22(1):134.

[11]HauserSL, CreeBAC, 2020. Treatment of multiple sclerosis: a review. Am J Med, 133(12):1380-1390.E2.

[12]HuangJ, ZhangYW, DongL, et al., 2018. Ethnopharmacology, phytochemistry, and pharmacology of Cornus officinalis sieb. et Zucc. J Ethnopharmacol, 213:280-301.

[13]KleinewietfeldM, HaflerDA, 2014. Regulatory T cells in autoimmune neuroinflammation. Immunol Rev, 259(1):231-244.

[14]KunklM, FrascollaS, AmorminoC, et al., 2020. T helper cells: the modulators of inflammation in multiple sclerosis. Cells, 9(2):482.

[15]LassmannH, BradlM, 2017. Multiple sclerosis: experimental models and reality. Acta Neuropathol, 133(2):223-244.

[16]LeeGR, 2018. The balance of Th17 versus Treg cells in autoimmunity. Int J Mol Sci, 19(3):730.

[17]LiHH, HuFL, ZhangYL, et al., 2020. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. J Neurol, 267(12):3489-3498.

[18]LiZF, NieLL, ChenLP, et al., 2019. Rapamycin relieves inflammation of experimental autoimmune encephalomyelitis by altering the balance of Treg/Th17 in a mouse model. Neurosci Lett, 705:39-45.

[19]McCallB, 2019. Alemtuzumab to be restricted pending review, says EMA. Lancet, 393(10182):1683.

[20]McCoolR, WilsonK, ArberM, et al., 2019. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. Mult Scler Relat Disord, 29:55-61.

[21]MonacoS, NicholasR, ReynoldsR, et al., 2020. Intrathecal inflammation in progressive multiple sclerosis. Int J Mol Sci, 21(21):8217.

[22]MoserT, AkgünK, ProschmannU, et al., 2020. The role of Th17 cells in multiple sclerosis: therapeutic implications. Autoimmun Rev, 19(10):102647.

[23]OhJ, Vidal-JordanaA, MontalbanX, 2018. Multiple sclerosis: clinical aspects. Curr Opin Neurol, 31(6):752-759.

[24]ParkJS, LeeJ, LimMA, et al., 2014. JAK2-STAT3 blockade by AG490 suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T cells and Th17 cells. J Immunol, 192(9):4417-4424.

[25]PawlakM, HoAW, KuchrooVK, 2020. Cytokines and transcription factors in the differentiation of CD4⁺ T helper cell subsets and induction of tissue inflammation and autoimmunity. Curr Opin Immunol, 67:57-67.

[26]PegorettiV, SwansonKA, BetheaJR, et al., 2020. Inflammation and oxidative stress in multiple sclerosis: consequences for therapy development. Oxid Med Cell Longev, 2020:7191080.

[27]PitarokoiliK, AmbrosiusB, GoldR, 2017. Lewis rat model of experimental autoimmune encephalomyelitis. Curr Protoc Neurosci, 81:9.61.1-9.61.20.

[28]Pulido-ValdeolivasI, AndorràM, Gómez-AndrésD, et al., 2020. Retinal and brain damage during multiple sclerosis course: inflammatory activity is a key factor in the first 5 years. Sci Rep, 10:13333.

[29]QuZ, ZhengN, ZhangYF, et al., 2016. Preventing the BDNF and NGF loss involved in the effects of cornel iridoid glycoside on attenuation of experimental autoimmune encephalomyelitis in mice. Neurol Res, 38(9):831-837.

[30]QuZ, ZhengN, WeiYZ, et al., 2019. Effect of cornel iridoid glycoside on microglia activation through suppression of the JAK/STAT signalling pathway. J Neuroimmunol, 330:96-107.

[31]RuizF, VigneS, PotC, 2019. Resolution of inflammation during multiple sclerosis. Semin Immunopathol, 41(6):711-726.

[32]SchneiderC, SchuetzG, ZollnerTM, 2009. Acute neuroinflammation in lewis rats—a model for acute multiple sclerosis relapses. J Neuroimmunol, 213(1-2):84-90.

[33]SegalBM, 2019. The diversity of encephalitogenic CD4⁺ T cells in multiple sclerosis and its animal models. J Clin Med, 8(1):120.

[34]StenagerE, 2019. A global perspective on the burden of multiple sclerosis. Lancet Neurol, 18(3):227-228.

[35]XieXJ, YeYF, ZhouL, et al., 2010. Th17 promotes acute rejection following liver transplantation in rats. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 11(11):819-827.

[36]YinLL, ChenYY, QuZ, et al., 2014. Involvement of JAK/STAT signaling in the effect of cornel iridoid glycoside on experimental autoimmune encephalomyelitis amelioration in rats. J Neuroimmunol, 274(1-2):28-37.

[37]ZhaoPY, WangYQ, LiuXH, et al., 2018. Bu Shen Yi Sui capsule promotes remyelination correlating with Sema3A/NRP-1, LIF/LIFR and Nkx6.2 in mice with experimental autoimmune encephalomyelitis. J Ethnopharmacol, 217:36-48.

[38]ZhaoST, WangCZ, 2018. Regulatory T cells and asthma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 19(9):663-673.